Senzime (Nasdaq Stockholm: SEZI) (OTCQX: SNZZF), a provider of perioperative patient monitoring solutions, announced on Monday that it has launched its advanced TetraGraph system for quantitative train-of-four (TOF) monitoring at ANESTHESIOLOGY 2024.
Featuring TetraGraph Adaptive Intelligence, a smart algorithm suite, the device enables real-time, precision-based neuromuscular assessments and seamless automated workflows across the perioperative process.
The next-generation TetraGraph incorporates an intuitive Level-of-Block Gauge for simplified TOF monitoring, aligning with updated clinical guidelines, and a cutting-edge EMG algorithm delivering 4x higher resolution. This enhanced functionality aims to address residual neuromuscular block (rNMB) complications, which impact many surgical patients, improving patient safety and clinical outcomes.
With sustainable, upgradable software, the new TetraGraph is designed for long-term use, adapting to evolving healthcare demands. US shipments will commence in Q4 2024, available on a first-come, first-serve basis.
With solutions in over 30 countries, Senzime continues to advance patient safety and recovery worldwide.
Akura Medical's application for trial of Katana Thrombectomy System receives US FDA approval
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
PharmaNutra signs agreement with strategic consulting firm for US development plan
BD launches advanced Intraosseous Vascular Access System for rapid emergency use
Pulsenmore to supply 25,000 home ultrasound devices to Clalit Health Services
Medtronic announces new, long-term data from SPYRAL HTN-ON MED clinical trial
Senzime unveils next-gen TetraGraph TOF monitor at ANESTHESIOLOGY 2024; US shipments to begin in Q4
Abbott launches new clinical trial to improve results in patients with advanced heart failure
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Adocia patents stable hormone combinations for obesity and diabetes